Literature DB >> 12015920

Management of HIV-infected Patients with Multidrug-resistant Virus.

Julio S.G. Montaner1, Marianne Harris.   

Abstract

Heavily pretreated HIV-infected patients with multidrug-resistant virus remain a clinical challenge to the treating physician. While the goal of therapy in such patients is still controversial, sustained immunologic and clinical benefit have only been demonstrated with complete suppression of plasma viral load below detectable levels. Expert use of resistance testing may help in the selection of the salvage regimen, and monitoring of plasma drug levels may help optimize the potency and tolerability, especially of complex, multiple drug regimens where adherence remains a critical determinant of treatment outcome. The potential roles of newer agents, adjuvants, treatment interruptions, and immune-based therapies remain under investigation.

Entities:  

Year:  2002        PMID: 12015920     DOI: 10.1007/s11908-002-0089-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  37 in total

1.  Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.

Authors:  S G Deeks; J N Martin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

2.  A compromise strategy for patients with multiple drug failure.

Authors:  J S Montaner; M Harris; R Harrigan; R Hogg; E Wood
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

3.  Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.

Authors:  Natasha Press; Gil Kimel; Marianne Harris; Benita Yip; Kevin J P Craib; Julio S G Montaner
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

4.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

5.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

6.  A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.

Authors:  J J Coull; D Turner; T Melby; M R Betts; R Lanier; D M Margolis
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

7.  Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.

Authors:  J H Condra; C J Petropoulos; R Ziermann; W A Schleif; M Shivaprakash; E A Emini
Journal:  J Infect Dis       Date:  2000-08-15       Impact factor: 5.226

8.  Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.

Authors:  D V Havlir; P B Gilbert; K Bennett; A C Collier; M S Hirsch; P Tebas; E M Adams; L J Wheat; D Goodwin; S Schnittman; M K Holohan; D D Richman
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

9.  "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; Mark W Tyndall; Christopher H Sherlock; Richard P Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-06-01       Impact factor: 3.731

10.  A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

Authors:  J S Montaner; C Zala; B Conway; J Raboud; P Patenaude; S Rae; M V O'Shaughnessy; M T Schechter
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

View more
  1 in total

1.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.